Ask Michael Burke Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Merritt who wrote (57739)	4/28/1999 12:15:00 AM
From: Stormin Norman	Read Replies (1) of 132070

Oh well, you win some, you lose some. MOUNTAIN VIEW, Calif., April 27 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO) announced today that the U.S. Food and Drug Administration did not approve the company's new drug application (NDA) for Natrecor(R) (nesiritide) in the treatment of acute episodes of congestive heart failure (CHF). Calling their action "a particularly difficult decision," the agency determined there are uncertainties remaining about the effectiveness and safety of Natrecor at this time necessitating further study of the drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next